ShangPharma Corporation (“ShangPharma”) was successfully listed on the New York Stock Exchange on 19th October, 2010.  ShangPharma is a China-based contract research provider, which provides a broad range of research and development services to international and Chinese pharmaceutical and biotechnology companies. In this public offering, we provided Hong Kong legal opinions in respect of ShangPharma's U.S. listing.